because today's payment model is not constructed to spread the cost," he said. "But that takes time." For state Medicaid programs, the challenge of affordability for the new sickle cell treatments ...
Hosted on MSN3mon
Makers of Sickle Cell Disease Gene Therapy to Participate in Payment Model, CMS SaysVertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia treatments, the agency announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback